Stifel initiated coverage of Inventiva with a Buy rating and $27 price target. The shares have benefited moderately from a revival of hope for NASH treatment and Inventiva’s oral pan-PPAR agonist is "one of few to have demonstrated both NASH resolution AND fibrosis improvement," the analyst tells investors. PPAR agonists also have shown metabolic benefit and lanifibranor could be suitable for the large subset with T2D co-morbidities, the analyst added.
Published first on TheFly
